ResearcherStavanger University HospitalNo recent work listed
Rune Smaaland
Matched on OpenAlex author ID A5084355420. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 11
2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper
Papers 5
- Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study. Co-author DOI 10.1186/s12885-022-09714-x↗
- Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12967-018-1677-2↗
- Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a natio… Co-author DOI 10.1186/s12893-017-0291-1↗
- Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Last author DOI 10.1016/j.molonc.2015.11.012↗
- Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Last author DOI 10.1002/ijc.28134↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kjersti Tjensvoll · 4 shared papers, 2014–2022 · strength 0.35
- Paper Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observatio… DOI 10.1186/s12885-022-09714-x↗
- Paper Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. DOI 10.1186/s12967-018-1677-2↗
- Paper Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. DOI 10.1002/ijc.28134↗
- Oddmund Nordgård · 4 shared papers, 2014–2022 · strength 0.35
- Paper Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observatio… DOI 10.1186/s12885-022-09714-x↗
- Paper Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. DOI 10.1186/s12967-018-1677-2↗
- Paper Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. DOI 10.1002/ijc.28134↗
- Bjørnar Gilje · 3 shared papers, 2016–2022 · strength 0.28
- Paper Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observatio… DOI 10.1186/s12885-022-09714-x↗
- Paper Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. DOI 10.1186/s12967-018-1677-2↗
- Paper Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. DOI 10.1016/j.molonc.2015.11.012↗
- Morten Lapin · 3 shared papers, 2016–2022 · strength 0.28
- Paper Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observatio… DOI 10.1186/s12885-022-09714-x↗
- Paper Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. DOI 10.1186/s12967-018-1677-2↗
- Paper Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. DOI 10.1016/j.molonc.2015.11.012↗
- Karin Hestnes Edland · 1 shared paper, 2022 · strength 0.15
- Milind M. Javle · 2 shared papers, 2016–2018 · strength 0.13
- Paper Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. DOI 10.1186/s12967-018-1677-2↗
- Paper Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. DOI 10.1016/j.molonc.2015.11.012↗
- Dag Hoem · 1 shared paper, 2017 · strength 0.07
- Svein Dueland · 1 shared paper, 2017 · strength 0.07
- Kristoffer Lassen · 1 shared paper, 2017 · strength 0.07
- Caroline Sophie Verbeke · 1 shared paper, 2017 · strength 0.07
- Knut Jørgen Labori · 1 shared paper, 2017 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.